BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Given Consensus Rating of “Moderate Buy” by Analysts

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) has been given a consensus rating of “Moderate Buy” by the fifteen analysts that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has issued a hold rating, eleven have given a buy rating and two have given a strong buy rating to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $390.00.

A number of brokerages have recently weighed in on ONC. Guggenheim lifted their price objective on BeOne Medicines from $410.00 to $420.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. Zacks Research raised BeOne Medicines from a “hold” rating to a “strong-buy” rating in a research report on Thursday, June 4th. Truist Financial reissued a “buy” rating and issued a $413.00 target price (up from $411.00) on shares of BeOne Medicines in a research report on Thursday, May 7th. Leerink Partners upped their target price on BeOne Medicines from $364.00 to $367.00 and gave the company an “outperform” rating in a research report on Friday, May 15th. Finally, Jefferies Financial Group cut BeOne Medicines from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $420.00 to $290.00 in a research report on Monday, March 16th.

Insider Activity at BeOne Medicines

In other BeOne Medicines news, COO Xiaobin Wu sold 1,292 shares of the stock in a transaction that occurred on Tuesday, June 23rd. The stock was sold at an average price of $276.26, for a total transaction of $356,927.92. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Lai Wang sold 1,068 shares of the stock in a transaction that occurred on Tuesday, June 23rd. The stock was sold at an average price of $276.74, for a total value of $295,558.32. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 27,236 shares of company stock worth $7,354,951 in the last ninety days. Company insiders own 6.19% of the company’s stock.

Hedge Funds Weigh In On BeOne Medicines

Hedge funds have recently bought and sold shares of the stock. EFG International AG purchased a new position in BeOne Medicines during the fourth quarter worth $25,000. Leonteq Securities AG acquired a new position in shares of BeOne Medicines in the 4th quarter valued at about $35,000. Daiwa Securities Group Inc. acquired a new position in shares of BeOne Medicines during the second quarter worth about $35,000. CWM LLC boosted its position in shares of BeOne Medicines by 32.8% in the fourth quarter. CWM LLC now owns 158 shares of the company’s stock worth $48,000 after buying an additional 39 shares during the period. Finally, Group One Trading LLC purchased a new stake in shares of BeOne Medicines in the fourth quarter worth about $61,000. Hedge funds and other institutional investors own 48.55% of the company’s stock.

BeOne Medicines Stock Performance

Shares of BeOne Medicines stock opened at $279.89 on Tuesday. BeOne Medicines has a one year low of $239.25 and a one year high of $385.22. The company has a market cap of $30.71 billion, a price-to-earnings ratio of 62.62 and a beta of 0.49. The company has a debt-to-equity ratio of 0.20, a quick ratio of 3.27 and a current ratio of 3.64. The business’s 50 day moving average price is $291.75 and its 200 day moving average price is $310.21.

BeOne Medicines (NASDAQ:ONC) last posted its earnings results on Wednesday, April 1st. The company reported $0.25 EPS for the quarter. BeOne Medicines had a return on equity of 12.06% and a net margin of 8.94%.The company had revenue of $1.51 billion for the quarter. On average, research analysts predict that BeOne Medicines will post 6.14 EPS for the current year.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.